VALN Stock Overview
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Valneva SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.30 |
| 52 Week High | €11.96 |
| 52 Week Low | €4.27 |
| Beta | 1.02 |
| 11 Month Change | -27.66% |
| 3 Month Change | -43.76% |
| 1 Year Change | -62.96% |
| 33 Year Change | -93.61% |
| 5 Year Change | n/a |
| Change since IPO | -84.84% |
Recent News & Updates
Recent updates
Valneva seeking a partnership for next-gen COVID-19 vaccine
Sep 26Valneva shows booster effect of COVID shot against AstraZeneca vaccine
Aug 29Valneva launches up to $75M at-the-market ADS offering program
Aug 15Valneva: Vaccine Business, Catalysts Ahead, And Pfizer's Lyme Love
Aug 08Valneva agrees to cut COVID vaccine supplies to EU
Jul 20Shareholder Returns
| VALN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.6% | 4.0% | 2.2% |
| 1Y | -63.0% | 18.3% | 32.6% |
Return vs Industry: VALN underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: VALN underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| VALN volatility | |
|---|---|
| VALN Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VALN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VALN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 700 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
| VALN fundamental statistics | |
|---|---|
| Market cap | US$343.21m |
| Earnings (TTM) | -US$7.79m |
| Revenue (TTM) | US$166.39m |
2.1x
P/S Ratio-44.1x
P/E RatioIs VALN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VALN income statement (TTM) | |
|---|---|
| Revenue | €158.54m |
| Cost of Revenue | €163.61m |
| Gross Profit | -€5.08m |
| Other Expenses | €2.34m |
| Earnings | -€7.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 20, 2025
| Earnings per share (EPS) | -0.046 |
| Gross Margin | -3.20% |
| Net Profit Margin | -4.68% |
| Debt/Equity Ratio | 79.4% |
How did VALN perform over the long term?
See historical performance and comparison